China
Africa
Explore chapters and articles related to this topic
Grazoprevir Combined with Elbasvir or Other Drugs
Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017
In this chapter we review the phase II and III clinical development programs of GZR–EBR (Zepatier). These trials have primarily included genotype 1 treatment-naive and -experienced patients both with and without cirrhosis and smaller numbers of patients with genotypes 2–6. Many drug development programs have included studies of patient subgroups such as those with HIV–HCV co-infection; the novelty of the GZR–EBR development program has been the inclusion of important patient subgroups, including chronic kidney disease, opioid-replacement therapy, and inherited blood disorders. Although the development of GZR–EBR is ongoing, these studies should provide high-quality data applicable to the treatment of a broad range of people with chronic HCV infection.
A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan
Published in Current Medical Research and Opinion, 2021
Jia-Hung Chen, Pei-Ning Wu, Sin-Chi Huang, Pao-Ju Hsu, Jason C. Hsu
Interferon (INF) for hepatitis C has low efficacy with serious side effects8, while the efficacy of new oral drugs (direct-acting antivirals, DAAs) is high9. They have also reduced side effects but are much more expensive. DAAs were approved for listing in Taiwan in December 2013, and they have been covered by National Health Insurance (NHI) since January 2017. DAAs that were covered by health insurance in Taiwan during 2017–2018 included Daklinza (daclatasvir; Bristol Myers Squibb, New York, NY), Sunvepra (asunaprevir; Bristol Myers Squibb, New York, NY), Viekirax (ombitasvir, paritaprevir, and ritonavir; AbbVie, Chicago, IL), Exviera (dasabuvir; AbbVie, Chicago, IL), Zepatier (elbasvir and grazoprevir; MSD, Kenilworth, NJ), Harvoni (ledipasvir and sofosbuvir; Gilead, Foster City, CA), Sovaldi (sofosbuvir; Gilead, Foster City, CA), and Maviret (glecaprevir and pibrentasvir; AbbVie, Chicago, IL).